StreetInsider.com News Articles

MoonLake reports week 52 phase 3 trial data for skin drug sonelokimab

Sun, 21 Jun 2026 17:00:20 -0400

MoonLake Immunotherapeutics (NASDAQ: MLTX) reported week 52 results from its Phase 3 VELA-1 and VELA-2 clinical trials evaluating sonelokimab in adults with moderate-to-severe hidradenitis suppurativa (HS), a chronic inflammatory skin condition.

Across both trials, 67.2% of patients treated with sonelokimab achieved HiSCR75, a measure of at least 75% reduction in abscess and inflammatory nodule count, and 33.1% achieved HiSCR100 at week 52 (n=396). Additionally, 26.0% of patients reached IHS4-100, defined as full inflammatory remission. The company said these figures exceed results reported in trials of competing agents at comparable endpoints.

Patient-reported outcomes also showed improvement. The mean HiSQOL score difference between baseline

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

Sun, 21 Jun 2026 17:00:00 -0400

Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents at the end of their respective parental trials
Namely, ~67% of patients treated with SLK achieved HiSCR75 at the one-year mark, with more than one quarter of patients achieving inflammatory remission (IHS4-100), and around one third reaching HiSCR100
Patients treated with SLK likewise showed substantial improvement in HiSQOL at Week 52, with a mean score

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

Sun, 21 Jun 2026 17:00:00 -0400

Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents at the end of their respective parental trials
Namely, ~67% of patients treated with SLK achieved HiSCR75 at the one-year mark, with more than one quarter of patients achieving inflammatory remission (IHS4-100), and around one third reaching HiSCR100
Patients treated with SLK likewise showed substantial improvement in HiSQOL at Week 52, with a mean score

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Xavier Ramnik

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667569.html

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Xavier Ramnik

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667569.html

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Moukheibir Catherine

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667572.html

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Moukheibir Catherine

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667572.html

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Loy Spike

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667573.html

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Loy Spike

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667573.html

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Phillips Andrew John

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667574.html

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Phillips Andrew John

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667574.html

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Bodenstedt Matthias

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667575.html

Form 4 MoonLake Immunotherapeut For: Jun 17 Filed by: Bodenstedt Matthias

Thu, 18 Jun 2026 18:45:00 -0400
si-local-file:///var/storage/secattach/20260618/26667575.html

Form 4 MoonLake Immunotherapeut For: Jun 15 Filed by: Reich Kristian

Wed, 17 Jun 2026 18:15:00 -0400
si-local-file:///var/storage/secattach/20260617/26661232.html

Form 4 MoonLake Immunotherapeut For: Jun 15 Filed by: Reich Kristian

Wed, 17 Jun 2026 18:15:00 -0400
si-local-file:///var/storage/secattach/20260617/26661232.html

Form 144 MoonLake Immunotherapeut Filed by: Reich Kristian

Mon, 15 Jun 2026 17:14:00 -0400
si-local-file:///var/storage/secattach/20260615/26648570.html

Form 144 MoonLake Immunotherapeut Filed by: Reich Kristian

Mon, 15 Jun 2026 17:14:00 -0400
si-local-file:///var/storage/secattach/20260615/26648570.html

Form 8-K MoonLake Immunotherapeut For: Jun 04

Tue, 09 Jun 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260609/26624157.html

Form 8-K MoonLake Immunotherapeut For: Jun 04

Tue, 09 Jun 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260609/26624157.html

H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

Mon, 08 Jun 2026 06:56:54 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $45.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).
The analyst commented: "Yesterday, MoonLake reported data from an open-label trial of its lead candidate sonelokimab (SLK) in axial spondyloarthritis (axSpA) at the European Alliance of Associations for Rheumatology (EULAR) Congress in London, UK. SLK delivered a compelling dataset in active axSpA, combining rapid and deep clinical responses with significant effects on imaging outcomes that provide an objective snapshot of the disease in action deep within the key pathological tissues. The company saw deep and meaningful responses across a broad range of clinical

Form 8-K MoonLake Immunotherapeut For: May 22

Mon, 01 Jun 2026 06:20:00 -0400
si-local-file:///var/storage/secattach/20260601/26578569.html

Form 8-K MoonLake Immunotherapeut For: May 22

Mon, 01 Jun 2026 06:20:00 -0400
si-local-file:///var/storage/secattach/20260601/26578569.html

Form SCHEDULE 13G/A MoonLake Immunotherapeut Filed by: Cormorant Asset Management, LP

Fri, 15 May 2026 13:26:00 -0400
si-local-file:///var/storage/secattach/20260515/26503292.html

Form SCHEDULE 13G/A MoonLake Immunotherapeut Filed by: Cormorant Asset Management, LP

Fri, 15 May 2026 13:26:00 -0400
si-local-file:///var/storage/secattach/20260515/26503292.html

Form 4 MoonLake Immunotherapeut For: May 11 Filed by: Bodenstedt Matthias

Wed, 13 May 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260513/26486050.html